Top Markets
#1 0G 0G +38.62%
#2 Merlin's Seal BTC Merlin's Seal BTC +37.25%
#3 Useless Coin Useless Coin +34.12%
#4 StonkBroker StonkBroker +31.74%
#5 Arbitrum Arbitrum +31.19%
#6 SAFEcoin SAFEcoin +28.71%
#7 Notcoin Notcoin +19.84%
#8 Pons Pons +18.99%
#9 Full Moon Full Moon +18.20%
#10 Curve DAO Curve DAO +16.10%
Coin of the day
0G 0G
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
EirGenix Inc. EirGenix Inc.

EirGenix Inc.

6589
Peringkat dalam Saham #14111
EirGenix Inc., founded in 2012 and based in New Taipei City, Taiwan, functions... EirGenix Inc., founded in 2012 and based in New Taipei City, Taiwan, functions as a contract development and manufacturing organization (CDMO) with operations spanning both domestic and international markets. The company offers a comprehensive range of services, encompassing cell line creation, process optimization, analytical testing and quality control, and current Good Manufacturing Practice (cGMP) compliant production utilizing both mammalian and microbial expression systems. They also specialize in services related to antibody-drug conjugates (ADCs). Beyond its service offerings, EirGenix is actively engaged in developing several therapeutic candidates. This pipeline includes EG12014/EGI014, a Trastuzumab biosimilar intended for cancer therapy, which has reached the biologics license application (BLA) submission stage. Other oncology-focused developments are EG1206A, a Pertuzumab biosimilar currently in Phase I clinical trials; EG13074, in preclinical development; and TSY0110(EG12043), an antibody-drug conjugate also in preclinical stages. Additionally, the company is advancing EG12021, a Bevacizumab biosimilar for cancer treatment, and EG62054, another biosimilar, both in preclinical development. In addition to its core activities, EirGenix manufactures and distributes a rapid antigen test for COVID-19, as well as the CRM197 carrier protein under the designation EG74032.
Harga Saham
$1.46
Terakhir disinkronkan: 2026-07-28
Kapitalisasi Pasar
$435.25M
Perubahan (1 hari)
-2.34%
Perubahan (1 tahun)
-26.63%
Negara
TW
Perdagangan EirGenix Inc. (6589)

Kategori

Healthcare
Margin Operasi untuk EirGenix Inc. (6589)
Margin Operasi per 2026 TTM: 0.00%
Menurut laporan keuangan dan harga saham terbaru dari EirGenix Inc., margin operasi saat ini (TTM) adalah 0.00%. Pada akhir 2026, margin operasi perusahaan adalah 0.00%.
Riwayat margin operasi untuk EirGenix Inc. dari 2026 hingga 2026
Margin Operasi pada akhir setiap tahun
Tahun Margin Operasi Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Margin Operasi untuk perusahaan sejenis atau pesaing
Perusahaan Margin Operasi Perbedaan Margin Operasi Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.